Clinical Trial Update: Sildenafil for Secondary Pulmonary Hypertension Due to Valvular Disease [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating sildenafil for secondary pulmonary hypertension due to valvular heart disease. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension
• Valvular Heart Disease

Drugs mentioned

• SILDENAFIL (SILDENAFIL)

Snippet

Sponsor: Hospital General Universitario Gregorio Marañon | Conditions: Pulmonary Hypertension, Valvular Heart Disease | Phase 4 | Status: COMPLETED